BGNE Co-Founder, Exec. Chairman

John V. Oyler

Co-Founder, Exec. Chairman

BGNE CEO

BGNE Pres, COO

Dr. Xiaobin  Wu Ph.D.

Pres, COO

BGNE GM of China

GM of China

BGNE Co-Founder, Chairman of the Scientific Advisory Board

Dr. Xiaodong  Wang Ph.D.

Co-Founder, Chairman of the Scientific Advisory Board

BGNE Non-Exec. Director

Non-Exec. Director

BGNE Consultant

Dr. Heng  Liang

Consultant

BGNE Chief Medical Officer of Hematology

Dr. Edna  Huang M.D.

Chief Medical Officer of Hematology

BGNE CFO

Julia  Wang

BGNE Principal Accounting Officer

Principal Accounting Officer

BGNE VP of Fin.

Daniel  Maller

VP of Fin.

BGNE Accounting

Accounting

BGNE Global Head of Technical Operations

Michael  Garvey

Global Head of Technical Operations

BGNE Sr. Director of Investor Relations

Mi  Zhou

Sr. Director of Investor Relations

BGNE Sr. VP

Scott  Samuels

Sr. VP

BGNE Gen. Counsel

Gen. Counsel

BGNE Core

Baekje Shenzhou is listed today at a price of 192.6 yuan/share

Baekje Shenzhou will raise 2.1 billion US dollars

Amgen acquired 20.5% shares of Baekje Shenzhou for US $2.7 billion

Baekje Shenzhou officially landed in HKEx today

Baekje Shenzhou received a new round of financing of 800 million US dollars

Baekje Shenzhou US stock IPO went public and raised 147 million US dollars

Baekje Shenzhou received US $97 million in round B financing

Baekje Shenzhou received $75 million in round A financing

百济神州今日上市 发行价格192.6元/股

安进27亿美元收购百济神州20.5%股份

百济神州获得8亿美元新一轮融资

百济神州美股IPO上市，融资1.47亿美元

百济神州获得9700万美元B轮融资

百济神州获得7500万美元A轮融资